IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11285209 B1

PDFFull Text
Date of Patent:
Mar. 29, 2022

Filed:

Apr. 10, 2020

Recombinant mva or mvaΔe3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors

Applicant:

Memorial Sloan Kettering Cancer Center, New York, NY (US);

Inventors:

Liang Deng, New York, NY (US);

Stewart Shuman, New York, NY (US);

Jedd Wolchok, New York, NY (US);

Taha Merghoub, New York, NY (US);

Weiyi Wang, New York, NY (US);

Peihong Dai, New York, NY (US);

Ning Yang, New York, NY (US);

Assignee:

MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY (US);

Attorney:

Foley & Lardner LLP

Primary Examiner:

Nianxiang Zou

Int. Cl.
CPC ...
C07K 14/475 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01); C12N 15/86 (2006.01); C07K 16/28 (2006.01); C07K 14/52 (2006.01); A61K 35/768 (2015.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 9/0019 (2013.01); A61K 35/768 (2013.01); A61K 39/0011 (2013.01); A61P 35/00 (2018.01); C07K 14/521 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12N 15/86 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55522 (2013.01); C07K 2317/76 (2013.01); C12N 2710/24032 (2013.01); C12N 2710/24121 (2013.01); C12N 2710/24132 (2013.01); C12N 2710/24143 (2013.01);
Abstract

The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of a recombinant modified vaccinia Ankara (MVA) virus comprising an MVA harboring a human Fms-like tyrosine kinase 3 ligand (hFlt3L) (MVA-hFtl3L). The foregoing vaccinia Ankara (MVA) virus can be delivered to tumor cells of a subject afflicted with a malignant solid tumor, to treat the tumor. In a related aspect, the present disclosure concerns a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MV At.E3L) modified to express human Fms-like 5 tyrosine kinase 3 ligand (hFlt3L) isolated, suitable for use as an immunotherapeutic agent against a malignant solid tumor.

Find Patent Forward Citations

Loading…